SCHEMBL4716506

SCHEMBL4716506

Nc1cc(Cl)nc(CC2CCCC2)n1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 2/20 0.38
CDK2 P24941 1/20 0.37
MAPT P10636 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
PDE2A O00408 1/20 0.32
KCNH2 Q12809 1/20 0.32
PNP P00491 1/20 0.31
CEL P19835 1/20 0.31
HTR3A P46098 1/20 0.31
PDE4A P27815 2/20 0.31
PDE4B Q07343 2/20 0.31
PDE4C Q08493 2/20 0.31
PDE4D Q08499 2/20 0.31
KDM5B Q9UGL1 2/20 0.31
MCHR1 Q99705 1/20 0.31
PDE8B O95263 1/20 0.30
KDM5A P29375 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15103664 0.98 HRH4 (0.40) HRH4CDK2MAPTTDP1PDE2A
SCHEMBL15103587 0.79 PDE2A (0.41) PDE2APDE4APDE4BPDE4CPDE4D
SCHEMBL3210565 0.72 HSP90AB1 (0.47) HRH4MAPT
SCHEMBL26907059 0.71 PDE2A (0.40) PDE2AKCNH2PDE4APDE4BPDE4C
SCHEMBL29770674 0.71 PDE2A (0.40) PDE2AKCNH2PDE4APDE4BPDE4C
SCHEMBL20671956 0.71 CDK2 (0.40) HRH4CDK2PNPHTR3AMCHR1
SCHEMBL18616362 0.71 CDK2 (0.40) HRH4CDK2PNPHTR3AMCHR1
SCHEMBL7454742 0.70 KDM5B (0.43) HRH4KCNH2PDE4APDE4BPDE4C
SCHEMBL5468464 0.70 MAPT (0.71) CDK2MAPTTDP1
SCHEMBL17625285 0.70 MAPT (0.41) CDK2MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1896428-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OP GABA B MEDIATED NERVOUS SYSTEM DISORDERS Novartis AG (CH) 2008-03-12 EP disclosed
WO-2006136442-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OP GABA B MEDIATED NERVOUS SYSTEM DISORDERS NOVARTIS AG (CH) 2006-12-28 WO disclosed